TY - JOUR
T1 - In Vivo Tracking of Human Hematopoiesis Reveals Patterns of Clonal Dynamics during Early and Steady-State Reconstitution Phases
AU - Biasco, Luca
AU - Pellin, Danilo
AU - Scala, Serena
AU - Dionisio, Francesca
AU - Basso-Ricci, Luca
AU - Leonardelli, Lorena
AU - Scaramuzza, Samantha
AU - Baricordi, Cristina
AU - Ferrua, Francesca
AU - Cicalese, Maria Pia
AU - Giannelli, Stefania
AU - Neduva, Victor
AU - Dow, David J.
AU - Schmidt, Manfred
AU - Von Kalle, Christof
AU - Roncarolo, Maria Grazia
AU - Ciceri, Fabio
AU - Vicard, Paola
AU - Wit, Ernst
AU - Di Serio, Clelia
AU - Naldini, Luigi
AU - Aiuti, Alessandro
PY - 2015/12/3
Y1 - 2015/12/3
N2 - Hematopoietic stem/progenitor cells (HSPCs) are capable of supporting the lifelong production of blood cells exerting a wide spectrum of functions. Lentiviral vector HSPC gene therapy generates a human hematopoietic system stably marked at the clonal level by vector integration sites (ISs). Using IS analysis, we longitudinally tracked >89,000 clones from 15 distinct bone marrow and peripheral blood lineages purified up to 4 years after transplant in four Wiskott-Aldrich syndrome patients treated with HSPC gene therapy. We measured at the clonal level repopulating waves, populations’ sizes and dynamics, activity of distinct HSPC subtypes, contribution of various progenitor classes during the early and late post-transplant phases, and hierarchical relationships among lineages. We discovered that in-vitro-manipulated HSPCs retain the ability to return to latency after transplant and can be physiologically reactivated, sustaining a stable hematopoietic output. This study constitutes in vivo comprehensive tracking in humans of hematopoietic clonal dynamics during the early and late post-transplant phases.
AB - Hematopoietic stem/progenitor cells (HSPCs) are capable of supporting the lifelong production of blood cells exerting a wide spectrum of functions. Lentiviral vector HSPC gene therapy generates a human hematopoietic system stably marked at the clonal level by vector integration sites (ISs). Using IS analysis, we longitudinally tracked >89,000 clones from 15 distinct bone marrow and peripheral blood lineages purified up to 4 years after transplant in four Wiskott-Aldrich syndrome patients treated with HSPC gene therapy. We measured at the clonal level repopulating waves, populations’ sizes and dynamics, activity of distinct HSPC subtypes, contribution of various progenitor classes during the early and late post-transplant phases, and hierarchical relationships among lineages. We discovered that in-vitro-manipulated HSPCs retain the ability to return to latency after transplant and can be physiologically reactivated, sustaining a stable hematopoietic output. This study constitutes in vivo comprehensive tracking in humans of hematopoietic clonal dynamics during the early and late post-transplant phases.
UR - http://www.scopus.com/inward/record.url?scp=84969884860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969884860&partnerID=8YFLogxK
U2 - 10.1016/j.stem.2016.04.016
DO - 10.1016/j.stem.2016.04.016
M3 - Article
SN - 1934-5909
VL - 19
SP - 107
EP - 119
JO - Cell Stem Cell
JF - Cell Stem Cell
IS - 1
ER -